论文部分内容阅读
目的提高成人ALL的有效治疗 ,尝试应用去甲氧柔红霉素 (IDA)治疗成人ALL。 方法初发成人ALL病例共 2 8例 ;采用标准的VDP或VDLP方案 :IDA治疗组 (17例 )和柔红霉毒 (DNR)治疗组 (11例 ) ;并对两组的近期疗效进行比较。 结果诱导化疗IDA组缓解率为 82 .4% (14/17) ,早期死亡率 17.6 % ;DNR组缓解率 90 .9% ,早期死亡率 9.1% ,两组无明显差异 (P >0 .0 5 )。巩固化疗疗效 :生存分析曲线示IDA组 10个月无复发生存为41.7% ,总生存率为 83.3% ;而DNR组为 2 3.3%和 37.5 %。两组比较虽无明显差异 ,但仍提示提高缓解质量的趋势。 结论IDA诱导缓解率与DNR组相近 ,但有可能延长持续缓解时间 ;更为重要的是必须加强缓解后治疗强度才能提高长期疗效。
Objective To improve the effective treatment of adult ALL and try to apply demethoxyribine (IDA) to treat adult ALL. Methods A total of 28 ALL patients were enrolled in this study. Standard VDP or VDLP regimens were used: IDA treatment group (17 cases) and daunorubicin (DNR) treatment group (11 cases); and the short-term effects of the two groups were compared . Results The response rate was 82.4% (14/17) in IDA group and 17.6% in early stage. The remission rate in DNR group was 90.9%, and the early mortality rate was 9.1%. There was no significant difference between two groups (P> 0.05) 5). Consolidation of chemotherapy efficacy: Survival analysis showed IDA group 10 months recurrence-free survival was 41.7%, overall survival rate was 83.3%; and DNR group was 23.3% and 37.5%. Although no significant difference between the two groups, but still prompted to improve the quality of the trend to ease. Conclusions IDA induced remission rate is similar to DNR group, but it may prolong the duration of remission; more importantly, it is necessary to strengthen the intensity of remission therapy to improve long-term efficacy.